Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: Challenges and opportunities

Alain H. Litwin, Irene Soloway, Marc Gourevitch

Research output: Contribution to journalArticle

Abstract

Despite the high prevalence of hepatitis C virus (HCV) infection among drug users enrolled in methadone maintenance treatment programs, few drug users are being treated with combination therapy. The most significant barrier to treatment is lack of access to comprehensive HCV-related care. We describe a pilot program to integrate care for HCV infection with substance abuse treatment in a setting of maintenance treatment with methadone. This on-site, multidisciplinary model of care includes comprehensive screening and treatment for HCV infection, assessment of eligibility, counseling with regard to substance abuse, psychiatric services, HCV support groups, directly observed therapy, and enhanced linkages to a tertiary care system for diagnostic procedures. Our approach has led to high levels of adherence, with liver biopsy and substantial rates of initiation of antiviral therapy. Two cases illustrate the successful application of this model to patients with HCV infection complicated by active substance abuse and psychiatric comorbidity.

Original languageEnglish (US)
JournalClinical Infectious Diseases
Volume40
Issue numberSUPPL. 5
DOIs
StatePublished - Apr 15 2005

Fingerprint

Methadone
Drug Users
Hepacivirus
Injections
Virus Diseases
Substance-Related Disorders
Therapeutics
Psychiatry
Directly Observed Therapy
Self-Help Groups
Tertiary Healthcare
Antiviral Agents
Comorbidity
Counseling
Biopsy
Liver

ASJC Scopus subject areas

  • Immunology

Cite this

Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment : Challenges and opportunities. / Litwin, Alain H.; Soloway, Irene; Gourevitch, Marc.

In: Clinical Infectious Diseases, Vol. 40, No. SUPPL. 5, 15.04.2005.

Research output: Contribution to journalArticle

@article{da9561d9a7604e2a96c410e1548b4458,
title = "Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: Challenges and opportunities",
abstract = "Despite the high prevalence of hepatitis C virus (HCV) infection among drug users enrolled in methadone maintenance treatment programs, few drug users are being treated with combination therapy. The most significant barrier to treatment is lack of access to comprehensive HCV-related care. We describe a pilot program to integrate care for HCV infection with substance abuse treatment in a setting of maintenance treatment with methadone. This on-site, multidisciplinary model of care includes comprehensive screening and treatment for HCV infection, assessment of eligibility, counseling with regard to substance abuse, psychiatric services, HCV support groups, directly observed therapy, and enhanced linkages to a tertiary care system for diagnostic procedures. Our approach has led to high levels of adherence, with liver biopsy and substantial rates of initiation of antiviral therapy. Two cases illustrate the successful application of this model to patients with HCV infection complicated by active substance abuse and psychiatric comorbidity.",
author = "Litwin, {Alain H.} and Irene Soloway and Marc Gourevitch",
year = "2005",
month = "4",
day = "15",
doi = "10.1086/427450",
language = "English (US)",
volume = "40",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "SUPPL. 5",

}

TY - JOUR

T1 - Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment

T2 - Challenges and opportunities

AU - Litwin, Alain H.

AU - Soloway, Irene

AU - Gourevitch, Marc

PY - 2005/4/15

Y1 - 2005/4/15

N2 - Despite the high prevalence of hepatitis C virus (HCV) infection among drug users enrolled in methadone maintenance treatment programs, few drug users are being treated with combination therapy. The most significant barrier to treatment is lack of access to comprehensive HCV-related care. We describe a pilot program to integrate care for HCV infection with substance abuse treatment in a setting of maintenance treatment with methadone. This on-site, multidisciplinary model of care includes comprehensive screening and treatment for HCV infection, assessment of eligibility, counseling with regard to substance abuse, psychiatric services, HCV support groups, directly observed therapy, and enhanced linkages to a tertiary care system for diagnostic procedures. Our approach has led to high levels of adherence, with liver biopsy and substantial rates of initiation of antiviral therapy. Two cases illustrate the successful application of this model to patients with HCV infection complicated by active substance abuse and psychiatric comorbidity.

AB - Despite the high prevalence of hepatitis C virus (HCV) infection among drug users enrolled in methadone maintenance treatment programs, few drug users are being treated with combination therapy. The most significant barrier to treatment is lack of access to comprehensive HCV-related care. We describe a pilot program to integrate care for HCV infection with substance abuse treatment in a setting of maintenance treatment with methadone. This on-site, multidisciplinary model of care includes comprehensive screening and treatment for HCV infection, assessment of eligibility, counseling with regard to substance abuse, psychiatric services, HCV support groups, directly observed therapy, and enhanced linkages to a tertiary care system for diagnostic procedures. Our approach has led to high levels of adherence, with liver biopsy and substantial rates of initiation of antiviral therapy. Two cases illustrate the successful application of this model to patients with HCV infection complicated by active substance abuse and psychiatric comorbidity.

UR - http://www.scopus.com/inward/record.url?scp=16844376913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16844376913&partnerID=8YFLogxK

U2 - 10.1086/427450

DO - 10.1086/427450

M3 - Article

C2 - 15768345

AN - SCOPUS:16844376913

VL - 40

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - SUPPL. 5

ER -